Firefighters battle for occupational cancer benefits
ASHEVILLE, North Carolina (WLOS) Cancer caused 66-percent of career firefighter line of duty deaths nationwide between 2002 and 2019 according to data from the International Association of Fire Fighters.
The reason why is the focus of News 13’s Deadlier than Fire series and documentary following several firefighters through their cancer battle.
At least 257 North Carolina firefighters from 77 departments have been diagnosed with cancer over the last decade according to a 2020 Health and Safety Survey done by the North Carolina Association of Fire Chiefs. Right now, the biggest battle is a lack of data and how to account for whether the job is putting firefighters at a greater risk. That’s slowly changing as states including North Carolina recognize collecting data concerning cancer cases among firefighters and conducting better research are the only way to better understand what appear to be increasing cases.
4SC AG: 4SC präsentiert auf dem virtuellen 10th World Congress of Melanoma and 17th EADO Congress
pressetext.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pressetext.com Daily Mail and Mail on Sunday newspapers.
Secura Bio gibt Abschluss der COPIKTRA-(duvelisib)-Studie (PRIMO) zu peripherem T-Zell-Lymphom bekannt
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
ResearchAndMarkets.com’s offering.
This report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Anti-CD30 therapies pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Anti-CD30 therapies R&D. The therapies under development are focused on novel approaches for Anti-CD30 therapies.
Anti-CD30 therapies Emerging Drugs Chapters
This segment of the Anti-CD30 therapies report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological ac